Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (December 2017)

29 slides from Sorrento Therapeutics's investor presentation, December 2017

  1. Slide 1: Corporate Investor Presentation

    Corporate Investor Presentation December 2017 V121617

  2. Slide 2: Disclaimer

    Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking

  3. Slide 3: Developing Immuno-Oncology and CAR-T Therapies

    Developing Immuno-Oncology and CAR-T Therapies © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 3

  4. Slide 4: Recent Achievements and Lead Development Programs

    Recent Achievements › ZTlido™ (lidocaine topical system) 1.8% o Submission of FDA NDA (3Q17) o Europe MAA Submission (4Q17) › RTX (resiniferatoxin) o FDA IND authorization (2Q17) › CD38 CAR-T o Pre-IND Meeting with FDA (3Q17) Lead Development Programs IND Phase 1 Phase 2 Phase 3 NDA submission ZTlid

  5. Slide 5: Outlook of CAR-T Therapies

    Outlook of CAR-T Therapies CD19 BCMA CD38 SORRENTO/CELULARITY New Frontier CD38 CAR-T Autologous Allogeneic Multiple CAR-T CAR-T Myeloma Novartis, Kite/Gilead, Juno, Cellectis/Servier/Pfizer Bluebird, GenScript SORRENTO/CELULARITY SORRENTO © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 5

  6. Slide 6: Sorrento CD38 CAR-T Program: A Very Big Opportunity

    Sorrento CD38 CAR-T Program: A Very Big Opportunity › Addressing Multiple Myeloma indication => $22 B market opportunity › Targeting validated, high value CD38 target (Darzalex®: anti-CD38 mAb approved for MM treatment) › Proven CAR-T cell therapy modality for hematologic malignancies (Kymriah™ & Ye

  7. Slide 7: Hematological Malignancies in the US

    Hematological Malignancies in the US 82K ALL Patients (US) CD19: Novartis (Kymriah™) 2024 market forecast: $1B 662K NHL Patients (US) CD19: Kite (Yescarta™) 2024 market forecast: $5.4B CD38: Janssen/Genmab (Darzalex®) 120K MM Patients (US) CD38: Sorrento (CD38 CAR-T) 2023 market forecast: $22.6B CD3

  8. Slide 8: CAR-T Immune Therapies for Hematological Malignancies

    CAR-T Immune Therapies for Hematological Malignancies › CAR-T cell therapies are the “game-changer” therapeutic modalities against hematological malignancies. › CAR-T cell pricing (per patient) in the $350K to $500K range. › Anti-CD19 CAR-T Cell Therapies: • Kymriah™ (Novartis): ALL in children and

  9. Slide 9: The Simple Math

    The Simple Math 38 = 19 x 2 CD38 ≥ CD19 x 2 © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 9

  10. Slide 10: Industry-Leading CD38 CAR-T Program

    Industry-Leading CD38 CAR-T Program Sorrento CD38 CAR-T © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 10

  11. Slide 11: CD38 – Important Target for Immunotherapy of MM

    CD38 – Important Target for Immunotherapy of MM › Type II transmembrane glycoprotein with cyclic ADP ribose hydrolase activity › High density expression found in: o Multiple myeloma o Other B cell malignancies o Activated T cells o T cell malignancies © 2017 Sorrento Therapeutics, Inc. All Rights Re

  12. Slide 12: Sorrento – Most Advanced CD38 CAR-T Program in Development

    Sorrento – Most Advanced CD38 CAR-T Program in Development › CAR based on fully human anti-CD38 antibody o Different binding site than Darzalex® on CD38 o Different kinetic binding profile o Preference for high-expressing CD38 cells › Late stage IND-enabling studies o Projected IND filing date: 1H18

  13. Slide 13: Specific Killing of CD38 CAR-T Cells for CD38+ MM Cells

    Specific Killing of CD38 CAR-T Cells for CD38+ MM Cells › Selective killing of high expressing CD38+ cells E:T ratio = 1.25:1 No T cells Control T cells SRNE CD38 CAR-T cells A8 - R3 A4 - R3 B4 - R3 1000 R4: 33.443% 1000 R4: 23.560% 1000 R4: 2.306% K562 (CD38 negative cancer cells)/ SSC-H (10^3) SSC

  14. Slide 14: Anti-CD38 CAR-T Cells In Xenograft Mouse Model

    Anti-CD38 CAR-T Cells In Xenograft Mouse Model (RPMI8226 MM Tumors) Untreated Mice Treated with SRNE CD38- CAR T › On Day -23, immunodeficient NSG mice were Prior to treatment infused with human RPMI8226 MM tumor cells › On Day 0, CAR-T cells were administered i.v. 1 week after treatment › In all tr

  15. Slide 15: CAR-T cGMP Manufacturing Capabilities (2 Sites)

    CRITICAL INFRASTRUCTURE = “CAR-T” cGMP Manufacturing Capabilities (2 Sites) Providence West Coast East Coast San Diego Expected capacity: > 300 patients per year © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 15

  16. Slide 16: Industry-Leading CD38 ADC Program

    Industry-Leading CD38 ADC Program Sorrento CD38 ADC © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 16

  17. Slide 17: Anti-CD38 ADCs Inhibit Tumor Growth At Low Dose

    Anti-CD38 ADCs Inhibit Tumor Growth At Low Dose 2. IVIS @weekly or needed Daudi 2.6e7 on Day 0 Days after tumor cells 1. Body weight & clinical behavior monitor closely inoculation 0 7 14 21 28 35 42 49 …. Days after treatment Dara, CD38-A2: 1, 0.1 ug/mouse CD38-129: 1, 0.1 ug/Mouse CD38-136: 10, 1,

  18. Slide 18: Anti-CD38-ADCs are active against Daratumumab-resistant patient MM cells

    Anti-CD38-ADCs are active against Daratumumab-resistant patient MM cells Dara-sensitive RRMM Patients Dara-resistant RRMM Patients SRNE ADC-1 SRNE ADC-1 % Dead Cells (Annexin V+) % Dead Cells (Annexin V+) SRNE ADC-2 SRNE ADC-2 • Primary MM cells from relapsed/refractory multiple myeloma (RRMM) patie

  19. Slide 19: ADC cGMP Manufacturing Capabilities (2 Sites)

    CRITICAL INFRASTRUCTURE = ADC cGMP Manufacturing Capabilities (2 Sites) San Diego Suzhou › cGMP Ab manufacturing › cGMP Toxin manufacturing › cGMP ADC manufacturing › Fill and Finish © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 19

  20. Slide 20: Industry-Leading MM Expert Clinical Development Team

    Industry-Leading MM Expert Clinical Development Team Name Position(s) Jerome B. Zeldis, M.D., Chief Medical Officer › Track record of success Ph.D. & President of Clinical Development Ken Takeshita, MD Sr VP Clinical Research › Led development of MM drugs o IMIDs (more than $8B in revenue) Robert Kn

  21. Slide 21: Industry-Leading Off-the-Shelf CD38 CAR-T Program – CBA

    Industry-Leading Off-the-Shelf CD38 CAR-T Program – “CBA” (Cord Blood Allogeneic) Sorrento CD38 CAR-T “CBA” (Cord Blood Allogeneic) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 21

  22. Slide 22: Specific Killing of Anti-CD38 CAR-T CBA Cells for CD38+ MM Tumor Cell

    Specific Killing of Anti-CD38 CAR-T CBA Cells for CD38+ MM Tumor Cell E:T ratio = 1.25:1 No T Control T CAR-T E1 - R2 E3 - R2 Cancer cell mix 1 - R2 1000 R3: 56.0% R4: 44.0% 1000 R4: 74.8% R3: 25.2% 1000 R4: 95.8% R3: 4.2% SSC-H (10^3) SSC-H (10^3) SSC-H (10^3) PB Donor 8 500 500 500 0.001 0.001 0 1

  23. Slide 23: Eradication of CD38+ Human Multiple Myeloma in NSG Mice by CAR-T CBA Cells

    Eradication of CD38+ Human Multiple Myeloma in NSG Mice by Anti-CD38 CAR-T CBA Cells © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 23

  24. Slide 24: Summary of current CAR-T CBA Program

    Summary of current CAR-T CBA Program › CAR-T cells were successfully generated from Cord Blood. › CAR-T cells generated from CB produced much less cytokines than PB when activated by targeted antigen. › CAR-T cells generated from CB exhibited similar specific anti-tumor cytotoxicity as PB in vitro.

  25. Slide 25: Timetable and Upcoming Milestones

    Timetable and Upcoming Milestones Lead Development Programs IND Phase 1 Phase 2 Phase 3 NDA submission CD38 CAR-T (Multiple Myelom a) CD38 ADC (Multiple Myeloma) ZTlido™ (lidocaine topical system) 1.8% - pain associated w ith PHN PDUFA RTX (resiniferatoxin) - intractable pain (terminal cancer) RTX (

  26. Slide 26: Leading Players in the CAR-T Space

    Leading Players in the CAR-T Space CD19 CAR-T BCMA CAR-T BLUE JUNO $5.1 B $8.4 B (12/15/17) (12/15/17) CD38 CAR-T KITE $11.8 B SRNE (2017) $0.25 B (12/15/17) © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 26

  27. Slide 27: Sorrento's Rich Product Pipeline

    Sorrento’s Rich Product Pipeline Immuno-Oncology Platform Non-Opioid Pain Management Key Technology Assets Key Technology Assets Key Technology Assets › Extensive library of fully human antibodies (G-MAB™) › CAR-T therapy › TRPV1 Agonist - Neuron Ablating Agent (resiniferatoxin) › Biosimilars / Bio-

  28. Slide 28: Sorrento's Senior Leadership Team

    Sorrento’s Senior Leadership Team Name Position(s) Name Position(s) Jerome B. Zeldis, M.D., Chief Medical Officer Henry Ji, Ph.D. Chairman & CEO Ph.D. & President of Clinical Development EVP, Chief Administrative Officer & Chief George Ng, J.D. Mark Brunswick, Ph.D. VP Regulatory Affairs and Quality

  29. Slide 29: 4955 Directors Place, San Diego, CA 92121 [email protected]

    (858) 203-4100 4955 Directors Place, San Diego, CA 92121 [email protected] © 2017 Sorrento Therapeutics, Inc. All Rights Reserved 29

Sorrento Therapeutics — Investor Presentation (December 2017) on 6ix